Press Releases

Sepsis Therapeutics Market At a CAGR of 7.5% from 2022 to 2030

Share This Article

Third-generation Drugs and Antimicrobial Therapy to Combat Septic Infections

The severity of the septic process and the extent of organ dysfunction in patients require immediate admission to an ICU in hospital. To avoid extreme fatalities and admission to ICUs, healthcare companies in the sepsis therapeutics market are developing efficacious fourth- and fifth-generation drugs.

Revenue of cephalosporin drugs is projected to be the highest in 2027, in the sepsis therapeutics market, with an estimated value of ~US$ 2.2 billion. Thus, to gain positive outcome via clinical trials, manufacturers are collaborating with researchers & scientists to develop effective cephalosporin drugs. As such, healthcare institutions are approaching the combination therapy with third-generation cephalosporin and a tetracycline analogue to treat vibrio vulnificus infection in patients. This therapy has been gaining prominence in the sepsis therapeutics market, since the combination works as an ‘in vitro’ bactericidal activity against vibrio vulnificus.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111927

Healthcare professionals are increasingly adopting antimicrobial therapy to minimize the damage caused by infections to the gut microbiome. As such, healthcare providers in the sepsis therapeutics market are delivering the right balance between the utilization of antimicrobials and the clinical need for treating specific signs and symptoms in patients.

Immunometabolism Delivers Insights on New Therapeutic Targets

Healthcare companies in the sepsis therapeutics market are increasing research on immunometabolism, as insights on immune regulation are helping manufacturers develop efficacious drugs. Since the early detection and treatment of sepsis is critical, researchers are studying the body’s natural and innate response to various classes of drugs by studying immunometabolism. To gain further insights, healthcare companies are running clinical trials involving antibiotics, fluids, and dialysis, to ensure blood flow to the affected organs. They are also devising methods of surgical therapies to remove damaged tissues.

As such, healthcare companies in the sepsis therapeutics market are trying to identify new therapeutic targets that could potentially reduce inflammatory response in patients. They are increasing research via animal testing by introducing lipopolysaccharide (LPS) in mice to see if the molecule can suppress the severity of inflammatory response.

Judicious Prescriptions and New Antimicrobial Agents Reduce Drug Resistance

Antimicrobials have a rapid and long-lasting effect on septic infections. However, antimicrobial resistance to gram-positive infections (GPIs) is emerging as a major public health threat to patients, worldwide. The growing prevalence of multidrug-resistant bacteria in patients has led to increased morbidity and mortality rates. This has created the issue of escalated treatment costs and prolonged hospitalization stay for patients. This is why, healthcare companies in the sepsis therapeutics market are developing new antimicrobial agents to reduce the resistance of drugs against gram-positive infections.

Healthcare companies are expected to develop a robust healthcare value and supply chain in the Asia Pacific region, as it is predicted for fast growth in the sepsis therapeutics market. For instance, stakeholders in the sepsis therapeutics market have observed the growing prevalence of methicillin resistant staphylococcus aureus bacteria in Indian patients that has led to the heavy consumption of antibiotics. Thus, stakeholders in the sepsis therapeutics market are recommending judicious prescription of antimicrobial agents, implementation of antibiotic stewardship programs, and conformation to suitable antibiotic policies developed by health commissions to reduce the problem of drug resistance in patients

Analysts’ View of Sepsis Therapeutics Market

The sepsis therapeutics market is predicted to exponentially grow from a value of ~US$ 3.2 billion that was accounted in 2018, to a value of ~US$ 6 billion by 2027. Healthcare providers are practicing early therapeutic plasma exchange in cases of septic shock in patients. This method is considered medically safe, and effective for septic shock patients. They are also introducing high doses of vasopressors for rapid hemodynamic improvement and favorable changes in the cytokine profile for patients observed with septic shock. However, in the case of GPIs, adverse effects related to safety and tolerability towards drugs is an ongoing challenge for healthcare companies. To overcome this challenge, manufacturers should introduce new antimicrobial agents in efficacious fourth- and fifth-generation drugs.

Sepsis Therapeutics Market: Overview

The global sepsis therapeutics market for the historical year of 2017 and forecast period of 2019 to 2027, rise in investments in research & development and novel pipeline drugs are projected to boost the growth of the global sepsis therapeutics market during the forecast period.

The global sepsis therapeutics market generated ~US$ 3.2 Bn revenue in 2018, and is expected to expand at a CAGR of 7.5% from 2019 to 2027.

Novel Pipeline Drugs and Rise in Incidence Rate of Sepsis: A Key Driver

The geriatric population is prone to developing sepsis, and is expected to increase the patient pool across the world, which, in turn, is projected to drive the sepsis therapeutics market during the forecast period.

According to the United Nations University (UNU), the percentage of the world population above 65 years of age is anticipated to increase from 9% in 2010 to 16% by 2050.

Rise in the epidemiological burden of sepsis increases the demand for the development of drugs for the treatment of sepsis. This is likely to boost the growth of the sepsis therapeutics market.

Leading pharmaceutical companies are striving to address these unmet medical needs through new product development.

Asahi Kasei Corporation is planning to launch ART-123 by 2021 for the treatment of sepsis. The drug has shown positive results for phase III clinical trial for sepsis, which would support the advancement of drugs for phase IV studies.

View full report@ https://qyresearchmedical.com/report/sepsis-therapeutics-market-drug-class-aminoglycosides-cephalosporin-glycopeptide-antibiotics-others-route-of-administration-intravenous-oral-distribution-channel-hospital-pharmacies-retail-pharmacies-onl-019-2030/111927

New approval and commercialization of novel therapeutic drugs under clinical trial studies are projected to be a major driver of the global sepsis therapeutics market from 2019 to 2027.

Cephalosporin Drug Class Prominent

The cephalosporin segment dominated the global sepsis therapeutics market in 2018, and is expected to account for a major market share during the forecast period, as third-generation cephalosporins are commonly used to treat neonatal and infant sepsis. Cephalosporins also have the broadest gram-negative bacterial coverage. This is likely to drive the cephalosporin segment during the forecast period.

The others segment is projected to grow at significant CAGR during the forecast period. The use of combination therapy for the treatment of sepsis, such as cephalosporin plus an aminoglycoside, is a driving factor that is expected to propel the segment from 2019 to 2027.

Intravenous Administration Popular

The most common way to administer antibiotics is intravenously, as intravenous antibiotics reach tissues faster and at higher concentrations than oral antibiotics. The preference of the intravenous route for administration of drugs is expected to propel the segment during the forecast period.

North America to Dominate Global Sepsis Therapeutics Market

North America accounted for a major share of the global market in 2018, followed by Europe. The high prevalence and rise in incidence of sepsis in the U.S. and Canada, wide base of pharmaceutical companies in the U.S., and easy availability of drugs in the region were key factors responsible for the prominent share held by North America in the global sepsis therapeutics market in 2018.

According to a study published in the National Center for Biotechnology Information (NCBI), around 300 people per 100,000 individuals in the U.S. are affected by severe sepsis and septic shock

Europe was also an attractive market for sepsis therapeutics in 2018. High budget for research & development in the field of sepsis treatment and various initiatives taken by private and government institutions to promote awareness about sepsis are estimated to propel the market in Europe during the forecast period. Furthermore, well-established healthcare facilities, new product approvals, and commercialization and favorable medical reimbursement policies are anticipated to drive the market in the region.

The market in Asia Pacific is estimated to grow at a faster pace than other regions during the forecast period, due to increase in the focus on the development of healthcare infrastructure by public as well as private hospitals, along with a rise in the demand for novel therapeutics among a significant patient population. The sepsis therapeutics market in Asia Pacific is driven by a large pool of patients with sepsis in China and Japan, and rise in investments by leading players in the region for the establishment of distribution channels.

Global Sepsis Therapeutics Market: Competitive Landscape

Detailed profiles of the manufacturers of sepsis therapeutics have been provided in the report to evaluate their key product offerings, financials, business strategies, and recent developments.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111927/2900

Key players operating in the global sepsis therapeutics market include –

  • INOTREM S.A.
  • Mylan N.V.
  • Asahi Kasei Corporation
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • RegeneRx
  • Adrenomed AG
  • AtoxBio
  • Endacea, Inc.

Key Questions Answered in TMR’s Sepsis Therapeutics Market Study

  • What is the scope of growth of sepsis therapeutic companies in the pharmaceutical drugs sector?
  • What will be the Y-o-Y growth of the sepsis therapeutics market between the years 2019 and 2027?
  • What is the influence of the changing trends in the sepsis therapeutics market?
  • Will North America continue to remain the most profitable regional market for sepsis therapeutic providers?
  • Which factors will hamper the growth of the sepsis therapeutics market during the forecast period of 2019 to 2027?
  • Which are the leading companies in the global sepsis therapeutics market?

Segmentation of the Sepsis Therapeutics Market

Drug Class

  • Aminoglycosides
  • Cephalosporin
  • Glycopeptide Antibiotics
  • Others

Route of Administration

  • Intravenous
  • Oral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sepsis Therapeutics Market

4. Market Overview

4.1. Introduction

4.1.1. Drug Class Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Sepsis Therapeutics Market Analysis and Forecasts, 2017–2027

5. Market Outlook

5.1. Regulatory Scenario

5.2. Pipeline Analysis

6. Global Sepsis Therapeutics Market Analysis and Forecasts, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Drug Class, 2017–2027

6.3.1. Aminoglycosides

6.3.2. Cephalosporin

6.3.3. Glycopeptide Antibiotics

6.3.4. Others

6.4. Market Attractiveness, by Drug Class

7. Global Sepsis Therapeutics Market Analysis and Forecasts, by Route of Administration

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Route of Administration, 2017–2027

7.3.1. Intravenous

7.3.2. Oral

7.4. Market Attractiveness, by Route of Administration

8. Global Sepsis Therapeutics Market Analysis and Forecasts, by Distribution Channel

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Distribution Channel, 2017–2027

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Market Attractiveness, by Distribution Channel

9. Global Sepsis Therapeutics Market Analysis and Forecasts, by Region

9.1. Key Findings

9.2. Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Market Attractiveness, by Region

10. North America Sepsis Therapeutics Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value  Forecast, by Drug Class, 2017–2027

10.2.1. Aminoglycosides

10.2.2. Cephalosporin

10.2.3. Glycopeptide Antibiotics

10.2.4. Others

10.3. Market Value Forecast, by Route of Administration, 2017–2027

10.3.1. Intravenous

10.3.2. Oral

10.4. Market Value  Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

10.5. Market Value  Forecast, by Country, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. Market Attractiveness Analysis

10.6.1. By Drug Class

10.6.2. By Route of Administration

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Sepsis Therapeutics Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Drug Class, 2017–2027

11.2.1. Aminoglycosides

11.2.2. Cephalosporin

11.2.3. Glycopeptide Antibiotics

11.2.4. Others

11.3. Market Value Forecast, by Route of Administration, 2017–2027

11.3.1. Intravenous

11.3.2. Oral

11.4. Market Value  Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

11.5. Market Value Forecast by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Market Attractiveness Analysis

11.6.1. By Drug Class

11.6.2. By Route of Administration

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Sepsis Therapeutics Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Drug Class, 2017–2027

12.2.1. Aminoglycosides

12.2.2. Cephalosporin

12.2.3. Glycopeptide Antibiotics

12.2.4. Others

12.3. Market Value Forecast, by Route of Administration, 2017–2027

12.3.1. Intravenous

12.3.2. Oral

12.4. Market Value Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Market Value Forecast, by Country/Sub-region, 2017–2027

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Market Attractiveness Analysis

12.6.1. By Drug Class

12.6.2. By Route of Administration

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Sepsis Therapeutics Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Drug Class, 2017–2027

13.2.1. Aminoglycosides

13.2.2. Cephalosporin

13.2.3. Glycopeptide Antibiotics

13.2.4. Others

13.3. Market Value Forecast, by Route of Administration, 2017–2027

13.3.1. Intravenous

13.3.2. Oral

13.4. Market Value Forecast, by Distribution Channel, 2017–2027

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5. Market Value Forecast, by Country/Sub-region, 2017–2027

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Market Attractiveness Analysis

13.6.1. By Drug Class

13.6.2. By Route of Administration

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Sepsis Therapeutics Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Market Value  Forecast, by Drug Class, 2017–2027

14.2.1. Aminoglycosides

14.2.2. Cephalosporin

14.2.3. Glycopeptide Antibiotics

14.2.4. Others

14.3. Market Value Forecast, by Route of Administration, 2017–2027

14.3.1. Intravenous

14.3.2. Oral

14.4. Market Value  Forecast, by Distribution Channel, 2017–2027

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

14.5. Market Value  Forecast, by Country/Sub-region, 2017–2027

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Market Attractiveness Analysis

14.6.1. By Drug Class

14.6.2. By Route of Administration

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competitive Landscape

15.1. Market Player – Competition Matrix (By Tier and Size of companies)

15.2. Company Profiles

15.2.1. Mylan N.V.

15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.1.2. Product Portfolio

15.2.1.3. SWOT Analysis

15.2.1.4. Strategic Overview

15.2.1.5. Financial Overview

15.2.2. Asahi Kasei Corporation

15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.2.2. Product Portfolio

15.2.2.3. SWOT Analysis

15.2.2.4. Strategic Overview

15.2.2.5. Financial Overview

15.2.3. Pfizer, Inc.

15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.3.2. Product Portfolio

15.2.3.3. SWOT Analysis

15.2.3.4. Strategic Overview

15.2.3.5. Financial Overview

15.2.4. GlaxoSmithKline plc

15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.4.2. Product Portfolio

15.2.4.3. SWOT Analysis

15.2.4.4. Strategic Overview

15.2.4.5. Financial Overview

15.2.5. RegeneRx

15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.5.2. Product Portfolio

15.2.5.3. SWOT Analysis

15.2.5.4. Strategic Overview

15.2.5.5. Financial Overview

15.2.6. Adrenomed AG

15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.6.2. Product Portfolio

15.2.6.3. Strategic Overview

15.2.7. AtoxBio

15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.8. ENDACEA, INC.

15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.8.2. Product Portfolio

15.2.8.3. Strategic Overview

15.2.9. INOTREM S.A

15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.9.2. Product Portfolio

15.2.9.3. Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111927/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button